Background/Aims: Direct-acting antiviral (DAA) therapy has been shown to achieve a high rate of sustained virologic response (SVR) and favorable outcomes in chronic hepatitis C (CHC) patients. We investigated the virologic response and its clinical impact in CHC patients. Methods: CHC patients with compensated liver function treated with DAAs between 2016 and 2017 were included for retrospective analysis. We analyzed baseline characteristics and virologic and biochemical responses at on-treatment 4 weeks, end of treatment, and post-treatment 12 weeks. Fibrosis was measured as liver stiffness measurement by transient elastography (FibroScan). Adverse events were monitored during the treatment period. Results: A total of 135 patients (61.5% with genotype [GT] 1b and 38.5% with GT 2a) were enrolled 47.4% were male, 79.3% were treatment naive, and 30.4% had cirrhosis. SVR 12 was observed in 97.6% (81/83) in the GT 1b and 98.1% (51/52) in the GT 2a; treatment with daclatasvir+asunaprevir was the most commonly used in GT 1b (55/83), and sofosbuvir+ribavirin was the most commonly used in GT 2a (49/52). The median change of liver stiffness measurement at two time points using the signed rank test was -3.2 kPa in patients who underwent transient elastography before treatment and at SVR 12 (n=25). The most common adverse events were anemia, dyspepsia, and insomnia. One GT 2a patient treated with sofosbuvir+ribavirin stopped the treatment at 8 weeks due to symptomatic bradyarrhythmia; however, he recovered spontaneously and achieved SVR 12. Conclusions: DAA treatment of chronic hepatitis C genotype 1b and 2a resulted in a high rate of sustained virologic response and improvement of liver fibrosis score. (Korean J Gastroenterol 2018;72:197-204) 
INTRODUCTION

Chronic hepatitis C virus (CHC) infection is a serious health
problem affecting more than 180 million people worldwide. 1, 2 It became the leading cause of death from liver disease and liver transplantation in South Korea.
In the past several decades, the standard approach for patients with CHC was a combination of pegylated interferon and ribavirin therapy, and this regimen cured hepatic C virus (HCV) infection in approximately 50% of treated patients. 3, 4 
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The Korean Journal of Gastroenterology However, due to a low therapeutic success rate with relatively frequent side effects in patients with chronic kidney disease, its use was limited. 5 Since 2014, a new therapy has been developed using Interferon (IFN)-free direct-acting antiviral (DAA) agents, directly targeting HCV replication. Compared to the conventional IFN-therapy, DAA treatment resulted in sustained virologic response (SVR) rates of more than 90% with minimal side effects in many patient populations. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In 2015, the DAA treatment -after obtaining approval to be used with daclatasvir and asunaprevir -was widely adopted in South Korea and began to be regarded as the standard treatment for CHC infection. 16 However, to the best of our knowledge, there are limited studies on the treatment outcomes in Koreans. Hence, the purpose of this study was to evaluate the sustained virologic response (SVR 12) and safety of DAAs in Korean patients with CHC.
SUBJECTS AND METHODS
Study design
This was a single-center, retrospective cohort study evaluating the treatment regimens and outcomes of using DAA in Korean patients with CHC. This retrospective study was approved by the Institutional Review Board of Konkuk University Medical Center (KUH1010946). The requirement for informed consent was waived due to the retrospective nature.
Study patients
One hundred thirty-five consecutive patients who were treated with DAA for CHC at Konkuk University Medical Center in Korea between January 2016 and December 2017 were evaluated. All data were obtained from individual patient records.
We initially recorded the following results for all patients:
previous history of hepatitis C treatment, presence of liver cirrhosis when diagnosed, laboratory tests (hemoglobin, platelets, INR, albumin, AST, ALT, AFP) and history of comorbidities.
We evaluated the improvement of liver fibrosis by measuring the liver stiffness in patients who underwent transient elastog- 
Efficacy assessment
The viral load, HCV-RNA (PCR), was determined using a quantitative assay (COBAS® AmpliPrep/COBAS® TaqMan®; Roche Molecular Diagnostics, Pleasanton, CA, USA) and expressed in IU/mL (lower limit of quantification of 15 IU/mL). or at the end of treatment (relapse). Based on this, we calculated the success rate of therapeutic agent for each genotype.
Statistical analysis
All statistical analyses were performed by using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). The data were expressed as the mean±standard deviation for continuous variables and frequencies with percentages for categorical variables. We used the signed-rank test to assess significant change in the liver stiffness measurement (LSM) score and serum ALT of the Values are presented as mean±standard deviation or n (%). BMI, body mass index; HCV, hepatitis C virus; ALT, alanine transaminase; UNL, upper normal limit; FIB-4, fibrosis-4; GFR, glomerular filtration rate; RASs, resistance associated substitutions; OPr, ombitasvir/paritaprevir/ ritonavir; DCV, daclatasvir; ASV, asunaprevir. a RASs were not detected in all 55 patients who used DCV+ASV as the treatment. Of the 28 patients who selected other drugs, 12 patients did not undergo RASs test and among 5 patients, the RASs test was negative.
two time points, with significance set at the p<0.05.
RESULTS
Patient's characteristics
From January 2016 to December 2017, a total of 135 patients (61.5% with GT 1b and 38.5% with GT 2a) were enrolled and treated; 47.4% were male, 79.3% were treatment naive, and 30.4% had cirrhosis. The mean baseline HCV RNA levels were similar between the two genotypes, and the pre-treatment median ALT levels were elevated above the upper normal limit in both genotypes. All patients were followed-up for 12 weeks after DAA treatment. The baseline characteristics of the cohort are summarized in Table 1 .
Virological response
The overall SVR 12 rate of patients with HCV genotype 1b Table 2 ). Moreover, the SVR 12 rate, which was obtained by dividing the patient group into liver cirrhosis (LC) and non-LC, showed similar results in both genotypes (Fig. 1B) .
Biochemical response
Regardless of the treatment regimen, the serum ALT levels were significantly decreased in both genotypes 1b and 2a with before treatment (Fig. 2) .
LSM score
Among the 135 patients treated with DAA, 25 patients underwent both FibroScan before treatment and at 12 weeks Finally, he failed to follow-up. Table 3 shows the adverse events of the treatment regimen of genotype 1b and 2a. Out of the patients with genotype 1b (n=83), 17 had an adverse event (20.5%). The most common adverse events were dyspepsia (n=6, 7.2%), insomnia (n=3, 3.6%), and fatigue (n=3, 3.6%); however, there were no serious side effects that resulted in discontinuation of treatment. In the case of genotype 2a patients (n=52), most of the adverse events were anemia (defined as hemoglobin <10 g/dL or decreased hemoglobin >2 g/dL from baseline) due to ribavirin (31 out of 51, 60.8%). Although there was no discontinuation
Adverse events
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The Korean Journal of Gastroenterology Fig. 3 . LSM score (n=25). Significant improvement in the LSM score was observed after successful DAA treatment. LSM, liver stiffness measurement; kPa, kilopascal; Pre-Tx, pretreatment; SVR, sustained virologic response; DAA, direct-acting antiviral. Values are presented as n (%). Pts, patients; DAAs, direct-acting antivirals; Hb, hemoglobin; SOF, sofosbuvir; RBV, ribavirin; SVR, sustained virologic response. a Nausea (1), headache (1), skin rash (1), xeroderma (1), edema (1); b Defined as Hb <10 g/dL or decreased Hb >2 g/dL from baseline. Fourteen patients required dose reduction and 2 of them received blood transfusion; c One patient treated with SOF+RBV stopped treatment at 8 weeks due to symptomatic bradyarrhythmia. However, the patient recovered spontaneously and was found to have achieved SVR 12 during follow up.
of treatment due to anemia, 14 patients required dose reduction; two of them received blood transfusion.
One GT 2a patient treated with sofosbuvir+ribavirin stopped treatment at 8 weeks due to symptomatic bradyarrhythmia.
However, the patient recovered spontaneously and was found to have achieved SVR 12 during the follow-up period.
DISCUSSION
This study showed that DAA may be safe and effective for According to the biochemical test, serum ALT and AFP levels were considered as moderately accurate tests for indicating liver inflammation and fibrosis. 17, 18 In this study, platelet however, there were no serious adverse events that resulted in discontinued treatment. In genotype 2a patients, a high incidence of anemia during treatment was reported due to the use of ribavirin; however, there was no case of treatment discontinuation as a result of measures like adequate dose reduction and blood transfusion were taken as necessary.
After the end of DAA treatment, anemia was naturally improved without blood transfusion or iron pill administration.
In this study, during the follow-up period, two patients were There are some limitations to consider. First, our findings resulted from a single center study with a small study population. Therefore, the effect of statistical significance may be low. However, our results were comparable to previous large cohort studies. Second, our study was performed in a Korean population. Therefore, the findings here may not be applicable to other ethnic groups. Finally, the mean follow-up period after SVR 12 was not consistent depending on the patient's compliance because patients were referred to the outpatient clinic. Therefore, it is possible that the incidence of HCC during the follow-up period may have been underestimated. In conclusion, as the most common CHC genotype in Korea, the results of DAA treatment for 1b and 2a
showed high SVR 12 rates and improved liver fibrosis score without any significant difference in the treatment regimens.
